Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CEPI Expands COVID-19 Vaccine Portfolio, But Pleads For Big Funding Boost

Six Programs Now Under Way

Executive Summary

As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.

You may also be interested in...



Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone

Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.

Tech Transfer Roundup: Coronavirus Research Collaborations Respond To Pandemic

Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.

UK Assesses Firms’ Coronavirus Resilience

With the coronavirus outbreak gathering pace around the world, the UK is taking steps to assess companies’ ability to deal with potential medicine supply shortages, and has made additional funding available for vaccine and diagnostic research. Yet more funding to help the UK tackle the outbreak has just been announced in the 11 March budget.

Topics

UsernamePublicRestriction

Register

PS141840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel